Hotchkis & Wiley Capital Management LLC Acquires New Shares in Solventum Co. (NYSE:SOLV)

Hotchkis & Wiley Capital Management LLC bought a new position in Solventum Co. (NYSE:SOLV) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,799,880 shares of the company’s stock, valued at approximately $125,488,000.

Other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new stake in shares of Solventum during the first quarter valued at approximately $5,889,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Solventum during the first quarter valued at about $30,000. GAMMA Investing LLC acquired a new stake in Solventum during the 2nd quarter worth about $74,000. Massmutual Trust Co. FSB ADV bought a new position in shares of Solventum in the second quarter valued at $34,000. Finally, DNB Asset Management AS purchased a new stake in Solventum during the second quarter worth about $1,227,000.

Solventum Price Performance

Solventum stock opened at $71.95 on Tuesday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The firm has a 50 day moving average price of $70.55 and a 200-day moving average price of $62.58. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Ratings Changes

A number of brokerages have commented on SOLV. Morgan Stanley lifted their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Wells Fargo & Company lowered their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday, August 9th. Stifel Nicolaus started coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Wolfe Research initiated coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. Finally, BTIG Research started coverage on Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average price target of $68.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.